Healing peptide blend

KPV + GHK-Cu

KPV + GHK-Cu has an app half-life of 3.7 hours, modelled from its two components, and no study of the two peptides together was identified in PubMed or ClinicalTrials.gov.

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

KPV + GHK-Cu after one dose: 50% at ~3.7 h, 25% at 7.4 h, 12.5% at 11.1 h.

Drawn from the half-life in the app's model, ~3.7 h. The model's figures

KPV + GHK-Cu is a pre-mixed blend of two peptides, commonly sold as 10 mg KPV and 50 mg GHK-Cu per vial (60 mg in total), with vendor ratios that vary. The app's note adds that GHK-Cu carries copper, about 0.5 mg per 3 mg of GHK-Cu. KPV is a melanocortin-derived tripeptide, Lys-Pro-Val, written alpha-MSH(11-13) in one of the papers read.1,2 GHK is the tripeptide glycyl-L-histidyl-L-lysine, which a 2015 review says "naturally occurs in human plasma, saliva, and urine".3 The same review gives a plasma level of GHK of "about 200 ng/mL" at age 20 that "declines to 80 ng/mL by age 60", and proposes that GHK acts as a complex with copper.3 The app grades the evidence for the blend as emerging. What exists is separate for each peptide: a 2006 randomised skin trial and a registered wound trial of topical GHK-Cu, and cell and mouse work on KPV.4,5,2 A 2026 review of GHK-Cu states that "the clinical evidence remains sparse and does not meet contemporary active-entity quality standards".6

None of the findings below comes from a study of the blend, and the KPV findings come from cell lines and mice. Dalmasso and colleagues report that "KPV acts via PepT1 expressed in immune and intestinal epithelial cells" and that "Nanomolar concentrations of KPV inhibit the activation of NF-kappaB and MAP kinase inflammatory signaling pathways" in human cell lines.2 Kannengiesser and colleagues, working in two mouse colitis models, write that "These effects seem to be at least partially independent of MC1R signaling".1 In mice with crystal-induced peritonitis, Getting and colleagues conclude that KPV "is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1beta functions".7 In the same paper, macrophage release of KC and interleukin-1beta in vitro was inhibited by alpha-MSH and MTII "but not by KPV", whereas the Dalmasso work used epithelial and T-cell lines.7,2 For GHK-Cu, the 2015 review reports that GHK "can easily obtain copper 2+ bound to the high affinity copper transport site on plasma albumin".3 A 2026 review says the literature often handles GHK-Cu as a single active ingredient despite formulation-dependent variation in coordination state, speciation, stability, pharmacokinetics, and toxicity.6 The app's note states that no study has tested the two peptides together, so how they behave in a mixture is not described in the sources read.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3.7 h
Bioavailability
95%
Typical dose
1.2–3.6 mg/day
Route
SubQ
Time to peak
~0.5 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~3.7 h, mass-weighted from KPV at about 2 h and GHK-Cu at about 4 hNo half-life for KPV, GHK-Cu or the blend in people is given in the sources read, and PubMed returned 0 records for GHK subcutaneous pharmacokinetics; one review notes that "The tripeptide may be rapidly degraded in biological fluids; stability depends on route and matrix"6
Bioavailability95%No figure in the sources read; FDA states it "has not identified any human exposure data on drug products containing KPV administered via any route of administration"8
Time to peak~0.5 hNo time to peak reported in the sources read
ModelOne-compartment, SubQ, modelled from the component entriesThe app's note says neither component figure comes from a solid human SubQ study

A 2026 review lists "route-appropriate PK/biodistribution" among what systemic GHK-Cu claims "Require" before clinical extrapolation, and notes "no human exposure data" for pulmonary, neurological and systemic uses.6 None of the sources read gives an interval over which a level of either peptide stays measurable after a subcutaneous injection, so no level chart is drawn.

4

Human studies

No study of the blend was identified in PubMed or ClinicalTrials.gov, and none of the sources read reports a controlled trial of KPV in people, so the human record below is for GHK-Cu alone, applied to the skin. FDA's page states that it "has not identified any human exposure data on drug products containing KPV administered via any route of administration".8

Table 4.1Human studies3 rows
Study and yearDesignPeopleDose and lengthMain result
Miller and colleagues, Archives of Facial Plastic Surgery 20064Randomised comparison with blinded evaluators; funder not named in the record13 patients completed; circumoral skin resurfaced with a CO2 laserSkin regimens with or without topical GHK-Cu; assessed to 12 weeks (strength not stated in the record)No significant difference in erythema resolution; wrinkles and skin quality improved in all with no group difference; questionnaire score for overall skin quality higher with GHK-Cu (P = .04)
Eyebrow split-face study, 2026, as described in the Mateescu review6Randomised, double-blind, vehicle-controlled split-face; the original paper was not read18 healthy participants2% GHK-Cu serum for 12 weeksImproved eyebrow hair count and diameter "without serious adverse effects"; the review calls it "a small single-center study with a cosmetic endpoint and chemically undercharacterized test material"
CuHeal, NCT07437586, Hudson Biotech (lead sponsor, class industry)5Phase 2, randomised, double-blind, vehicle-controlled, split-wound; two 5-mm punch-biopsy wounds per person60 healthy adults aged 18 to 55 (estimated enrolment)0.1% w/w topical GHK-Cu gel, once daily for 14 days; assessed over 21 days with a 12-week scar visitStatus "RECRUITING"; the 2026 review reports no efficacy results posted by 12 August 20266

Deeper analysis: Miller and colleagues, GHK-Cu after CO2 laser resurfacing

Miller and colleagues, whose listed affiliation is Facial Aesthetic Concepts in San Clemente, California, reported the trial in Archives of Facial Plastic Surgery in 2006.4 Patients had circumoral skin resurfacing with a CO2 laser and were then randomised to posttreatment skin regimens with or without GHK-Cu; erythema was evaluated with computer software and blinded evaluators, and wrinkles and skin appearance were assessed 12 weeks after treatment.4 The authors conclude that GHK-Cu products "offered no significant reduction or resolution of posttreatment erythema" and that "Objective evaluation found no significant improvement in wrinkles or overall skin quality".4 The results section of the same record states that "All the patients experienced significant improvement in wrinkles and overall skin quality, but no differences were found between groups".4 They also report that "patient satisfaction was significantly higher for those who used GHK-Cu skin care products", a questionnaire result at P = .04 that sits beside the null objective results.4 The PubMed record carries a summary only: it gives no adverse events, discontinuations or limitations section, and its publication type reads "Research Support, Non-U.S. Gov't" without naming a funder.4 A 2026 review says the study "was negative on objective endpoints" and calls it "likewise underpowered but clinically important".6 The trial tested GHK-Cu on the skin; it did not include KPV, an injection or the blend.4

Deeper analysis: Dalmasso and colleagues, KPV and PepT1 in cells and mice

Dalmasso and colleagues reported the work in Gastroenterology in 2008; the authors write that the study "indicates tht KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD".2 Human cell lines (Caco2-BBE, HT29-Cl.19A and Jurkat) were stimulated with pro-inflammatory cytokines with or without KPV, and KPV was added to the drinking water of female C57BL/6 mice with DSS- or TNBS-induced colitis.2 The authors state that the dose "(100 μM KPV) was based on previous publications using α-MSH to treat experimental colitis".2 In the DSS model (5 mice per group) colonic myeloperoxidase activity was "significantly decreased by ~50%" with KPV, and in the TNBS model (10 mice per group) it was "significantly inhibited by ~30%".2 The methods section of the same paper states "N=10 mice/group", which differs from the 5 mice per group in the DSS figure legend.2 Among cytokines in the DSS model the KPV effect "was significant for IL-6 and IL-12", and KPV "did not change IL-10 mRNA expression in mouse colon".2 KPV given alone "had no effect on the basal MPO levels and other inflammatory parameters in the colonic mucosa", and the authors report a PepT1 affinity for KPV of "Km ~160 μM" in Caco2-BBE cells.2 The funding statement names the National Institutes of Health and the Crohn's and Colitis Foundation of America, and the authors state "No conflicts of interest exist".2 No limitations passage was located in the full text, and the work involved cell lines and mice only; no person was given KPV.2

Deeper analysis: Kannengiesser, Getting and Viennois, other KPV animal work

Kannengiesser and colleagues (University of Muenster, Inflammatory Bowel Diseases, 2008) tested KPV in DSS colitis and CD45RB(hi) transfer colitis in mice; the PubMed record states that in the DSS model "treatment with KPV led to earlier recovery and significantly stronger regain of body weight".1 In mice with a nonfunctional melanocortin-1 receptor, "KPV treatment rescued all animals in the treatment group from death during DSS colitis", and the authors write that "our data suggest KPV as an interesting therapeutic option for the treatment of IBD".1 The record gives no group sizes, dose, route, funder statement or limitations; its publication type reads "Research Support, Non-U.S. Gov't".1 Getting and colleagues (William Harvey Research Institute, Journal of Pharmacology and Experimental Therapeutics, 2003) report that systemic KPV in mice with crystal-induced peritonitis reduced the accumulation of polymorphonuclear leukocytes, and that the effect "was not blocked by the MC3/4-R antagonist".7 That record also lists "Research Support, Non-U.S. Gov't" and gives no numbers, dose, limitations or funder.7 Viennois and colleagues (Cellular and Molecular Gastroenterology and Hepatology, 2016) gave 100 μmol/L KPV in drinking water to mice in a colitis-associated cancer model, and report that KPV "was able to decrease the tumor number and the proliferation of malignant colonic epithelial cells in a PepT1-dependent way".9 The same paper found that mice with PepT1 overexpression "had larger tumor sizes, increased tumor burdens, and increased intestinal inflammation compared to WT mice", and that "When administered to PepT1-KO mice, KPV did not trigger any of the inhibitory effect on tumorigenesis observed in WT mice".9 Human colon biopsies in that paper showed "an increased expression of PepT1 in patients with colorectal cancer".9 The KPV was supplied by Biopeptide Co; funding came from the Department of Veterans Affairs, the National Institute of Diabetes and Digestive and Kidney Diseases and a Research Fellowship Award from the Crohn’s & Colitis Foundation of America, and the authors "disclose no conflicts".9

Deeper analysis: Pickart and colleagues, the GHK review

Pickart and colleagues, whose listed affiliation is Skin Biology in Bellevue, Washington, published the review in BioMed Research International in 2015 and declare no conflict of interests.3 The review concludes that "The molecule is very safe and no issues have ever arisen during its use as a skin cosmetic or in human wound healing studies".3 FDA's page, by contrast, states for injectable GHK-Cu that "There are limited data in humans to inform safety-related considerations", and a 2026 review describes the human efficacy evidence as "sparse, heterogeneous, and largely predates the active-entity quality standards".8,6 The 2026 review by Mateescu and colleagues lists a grant from Victor Babeș University of Medicine and Pharmacy Timișoara and writes that its own evidence classification is "author-defined" and "has not been externally validated".6

5

Doses reported in studies and on labels

A DailyMed search on 16 November 2026 returned no label for KPV and one label naming GHK-Cu, and no label dose for either peptide is tabled.

Table 5.1Doses reported in studies and on labels6 rows
SourceCompound and routeDose reportedContext
The appBlend, SubQ1.2 to 3.6 mg/day of blend, which the app's note converts to 1 to 3 mg GHK-Cu and 200 to 600 mcg KPV at a 1:5 ratioThe app's figure; not taken from a study or label
Dalmasso and colleagues, 20082KPV in drinking water, mice100 μMDSS colitis for 8 days (5 mice per group) and TNBS colitis for 48 hours (10 mice per group)
Viennois and colleagues, 20169KPV in drinking water, mice100 μmol/LGiven with DSS in two 7-day cycles in a colitis-associated cancer model
Pickart and colleagues, 20153GHK, injection in animal studies; estimate for humansThe authors estimate "about 100–200 mgs of GHK" for therapeutic actions in humans and add that "even this may overestimate" the effective dosageAn estimate from animal injection studies, not a trial dose; the authors write that "Future research is needed to establish the effective dosage in humans"
NCT07437586, planned5GHK-Cu gel, topical0.1% w/w, about 0.5 g once daily for 14 daysHealthy adults, 60 estimated; recruiting
Eyebrow split-face study, 20266GHK-Cu serum, topical2%18 healthy participants over 12 weeks, as described in a review

The GHK-Cu amount in the app's range (1 to 3 mg) is a small fraction of the 100–200 mg that Pickart and colleagues estimate, and neither figure comes from a trial of injected GHK-Cu.3 The same review also gives about 140 micrograms per injection for 10 days, scaled to the human body from rat bone-fracture studies that used a mixture of three small molecules.3

No adverse-event data for KPV in people were identified; FDA states it "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans".8 For injectable GHK-Cu, FDA states that compounded injectable drugs "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities".8 The skin studies of GHK-Cu report little on harms: the Miller record gives none, and the eyebrow study is described in a review as "without serious adverse effects".4,6 The registered wound trial lists safety as a secondary outcome (treatment-emergent adverse events, serious adverse events and withdrawals due to adverse events) and has no results.5 A 2026 review notes that "Angiogenesis is beneficial in ischemic and diabetic wounds but may be undesirable in tumors, proliferative retinopathies, or vascular malformations", in a passage on copper-binding peptides in repair models.6 A 2026 review of peptides in sports medicine, covering GHK-Cu among others, states that "rigorous human safety data are scarce, and there is potential for serious harm to patients".10 One of its two authors reports consulting fees from Arthrex "for activities unrelated to topics discussed in this article".10 A 2026 critical review that names KPV among peptides promoted in bodybuilding says "products are often mislabeled or contaminated" and that peptides "remain experimental substances with poorly defined long-term risks".11

7

Regulatory and anti-doping status

FDA's page on bulk drug substances nominated for compounding, current as of 22 April 2026, lists KPV and GHK-Cu (for injectable routes of administration) under substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators".8 A law-firm summary of FDA's April 2026 notice says FDA would remove 12 peptide bulk drug substances from "Category 2 of its Section 503A bulk drug substances list" and that "the FDA is removing one peptide, GHK-Cu, from Category 1".12 FDA's own page lists GHK-Cu (for injectable routes of administration) among the substances previously in category 2 whose nominations were withdrawn, while the summary describes the GHK-Cu removal as from Category 1; the sources read do not reconcile the two.8,12 The same summary says FDA would convene its Pharmacy Compounding Advisory Committee "at public meetings on July 23–24, 2026, and before the end of February 2027", and describes Category 2 as "significant safety risks identified; compounding not permitted".12 The sources read do not give the outcome of the July 2026 meeting. A 2026 article in the International Journal of Pharmaceutical Compounding by Willis and Vu lists KPV among its keywords and says it "examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders"; the PubMed record gives no conclusions on KPV.13 A DailyMed search on 16 November 2026 returned no label for KPV and no label for an injectable GHK-Cu product. The WADA Prohibited List 2026 text read does not name KPV or GHK-Cu.14 Section S0, "NON-APPROVED SUBSTANCES", covers any pharmacological substance not addressed in other sections and with no current approval by any governmental regulatory health authority for human therapeutic use, and lists it as prohibited at all times.14 Because the List names neither peptide, the sources read do not state how it classifies them.14

  • No study of KPV and GHK-Cu together was identified in PubMed or ClinicalTrials.gov, so the effect of one peptide on the other's absorption, stability or action is not described in the sources read.
  • The app's half-life, bioavailability and time to peak are modelled from the component entries, and no human measurement of either peptide's pharmacokinetics was identified.
  • The KPV studies read gave it in drinking water (Dalmasso, Viennois) and the record of one other (Getting) says "Systemic treatment"; whether subcutaneous KPV acts the same way in people is not described.2,9,7
  • Whether KPV's anti-inflammatory action runs through PepT1, melanocortin receptors or IL-1beta signalling differs between the papers read.2,1,7
  • Human evidence for GHK-Cu is limited to small topical studies, and the 2026 review states that the 13-participant post-laser study "was negative on objective endpoints".6
  • The contents of vendor vials are not described in the sources read for the blend, and a critical review states that peptide "products are often mislabeled or contaminated".11
What is the half-life of KPV + GHK-Cu?

The app lists about 3.7 hours, modelled from KPV at about 2 hours and GHK-Cu at about 4 hours. No half-life for either peptide or the blend in people was identified in the sources read, so the app's figure has no published figure beside it.

Is KPV + GHK-Cu approved by the FDA?

None of the sources read describes an FDA approval of KPV or of injectable GHK-Cu.8 FDA's page, current as of 22 April 2026, lists both among bulk drug substances nominated for compounding whose nominations were withdrawn.8

Is KPV + GHK-Cu banned by WADA?

The text of the WADA 2026 Prohibited List read does not name KPV or GHK-Cu.14 Section S0 prohibits at all times any pharmacological substance not addressed elsewhere in the List and with no current approval by any governmental regulatory health authority for human therapeutic use, and the sources read do not state whether it is applied to either peptide.14

Has KPV + GHK-Cu been studied in people?

No study of the two peptides together was identified in PubMed or ClinicalTrials.gov on 16 November 2026. For KPV, FDA states it "has not identified any human exposure data on drug products containing KPV administered via any route of administration".8

What is KPV?

KPV is the tripeptide Lys-Pro-Val, described as melanocortin-derived and written alpha-MSH(11-13) in one paper.2,1 Its reported anti-inflammatory effects in the papers read come from cell lines and mice.2,1

What is GHK-Cu?

GHK-Cu is the complex of the tripeptide glycyl-L-histidyl-L-lysine with copper 2+.3 A 2015 review says GHK "naturally occurs in human plasma, saliva, and urine".3

What is the ratio of KPV to GHK-Cu in the blend?

The app's note gives a common vial as 10 mg KPV and 50 mg GHK-Cu, a 1:5 ratio, and says vendor ratios vary.

What is the copper content of GHK-Cu?

The app's note gives about 0.5 mg of copper per 3 mg of GHK-Cu.

How does KPV + GHK-Cu differ from KLOW?

The app's note states that KLOW contains the same two peptides at the same amounts and adds BPC-157 and TB-500.

What did the human skin studies of GHK-Cu find?

A 2006 randomised trial in which 13 patients completed follow-up after CO2 laser resurfacing found no significant difference between groups in erythema resolution and no difference between groups in wrinkle or overall skin-quality improvement, with a higher questionnaire score for overall skin quality with GHK-Cu (P = .04).4 A 2026 review describes an 18-participant eyebrow study reporting improved hair count and diameter with a 2% GHK-Cu serum.6

11

References

  1. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008. PMID 18092346
  2. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008. PMID 18061177
  3. Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int 2015. PMID 26236730
  4. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PMID 16847171
  5. Hudson Biotech. Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal). ClinicalTrials.gov NCT07437586. NCT07437586
  6. Mateescu DM, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics 2026. PMID 42797253
  7. Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther 2003. PMID 12750433
  8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page content current as of 22 April 2026. FDA page
  9. Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol 2016. PMID 27458604
  10. Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med 2026. PMID 41966639
  11. Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. J Sports Med Phys Fitness 2026. PMID 41880199
  12. Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List. April 2026. Orrick summary
  13. Willis J, et al. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Int J Pharm Compd 2026. PMID 42752426
  14. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list